

Adaptimmune Therapeutics PLC  
Form 8-K  
January 08, 2016

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 7, 2016**

**ADAPTIMMUNE THERAPEUTICS PLC**

(Exact name of registrant as specified in its charter)

**England and Wales**  
(State or other jurisdiction of  
incorporation)

**1-37368**  
(Commission File Number)

**Not Applicable**  
(IRS Employer Identification No.)

**101 Park Drive, Milton Park  
Abingdon, Oxfordshire OX14 4RY**

**United Kingdom**

(Address of principal executive offices, including zip code)

**(44) 1235 430000**

## Edgar Filing: Adaptimmune Therapeutics PLC - Form 8-K

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Explanatory Note**

As previously announced, Adaptimmune Therapeutics plc (the Company) has voluntarily decided to issue the reports required by the Securities Exchange Act of 1934, as amended (the Exchange Act) on domestic company forms starting January 1, 2016. The Company has also changed its fiscal year from a June 30 to a December 31 fiscal year and as previously announced will file a Form 20-F transition report for the transition period from July 1, 2015 to December 31, 2015 by March 31, 2016 (the deadline required by the Exchange Act).

**Item 8.01. Other Events.**

On January 7, 2016, the Company issued a press release announcing that Professor P. Julian Dyson, Ph.D. has joined the Company as the head of the Autoimmune Group with responsibility for leading the expansion of the Company's T-cell therapy development activities to target certain autoimmune diseases.

A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein in its entirety.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits. The following exhibit is filed as part of this Report on Form 8-K:

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press Release dated January 7, 2016.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ADAPT IMMUNE THERAPEUTICS PLC

Date: January 8, 2016

By:

/s/ Margaret Henry  
Name: Margaret Henry  
Title: Corporate Secretary

**Exhibit Index**

**Exhibit No.**    **Description of Exhibit**

99.1            Press Release dated January 7, 2016.